Giuseppe Andò: Stable CAD + Oral Anticoagulation: Is Combination Therapy Still Justified?
Giuseppe Andò, Head of the Cardiology Department at Papardo University Hospital, shared on LinkedIn:
” Stable CAD + Oral Anticoagulation: Is Combination Therapy Still Justified?
For years, adding antiplatelet therapy to oral anticoagulation has been considered “safer.”
The evidence no longer supports this approach.
In the post-AQUATIC era, leveraging data from a large European RCT that expanded indications for OAC beyond atrial fibrillation, we conducted an updated meta-analysis of 6 randomized trials (n = 5,924) comparing OAC monotherapy vs OAC + SAPT in stable coronary artery disease.
OAC monotherapy delivers:
−51% major bleeding
Lower net adverse clinical events
Reduced cardiovascular mortality
No increase in ischemic events
Even more compelling: DOAC-based monotherapy significantly reduced MACE, with a clear treatment interaction.
Bottom line:
In patients with stable CAD requiring long-term anticoagulation, less is more.
OAC monotherapy—particularly with DOACs—should be the default strategy, especially in East Asian populations.
After AQUATIC, continuing routine combination therapy deserves serious reconsideration.”
Title: Oral anticoagulation with versus without antiplatelet therapy in patients with stable coronary artery disease and an indication for anticoagulation: a meta-analysis with trial sequential analysis
Authors: Ahmed Ibrahim, Ali Saad Al-Shammari, Shrouk Ramadan, Yousif Hameed Kurmasha, Khadeeja Ali Hamzah, M Rafiqul Islam, Muhammad Younas, Hritvik Jain, Yasar Sattar, Pierre Sabouret and Giuseppe Andò.
Read the full article.
Stay updated with Hemostasis Today.
-
May 24, 2026, 13:10Thomas Pincez: Emerging Challenges in Sickle Cell Disease Gene Therapy and Cancer Risk
-
May 24, 2026, 12:04Kalpana Gupta Shekhawat: Ferritin Is More Than an Iron Marker
-
May 24, 2026, 11:50Peter Zdziarski: Making Rare Disease Research More Human
-
May 24, 2026, 11:39Bram Berkelmans: Donating with a View
-
May 24, 2026, 11:28Ratiporn Chinthammit: A Meaningful Exchange in aHUS and PNH Education
-
May 24, 2026, 11:17Mary Ann Sromoski: Transfusion Medicine and Patient Blood Management in Practice
-
May 24, 2026, 07:45Thierry Burnouf: Advances in Platelet Membrane-Coated Nanoparticles for Targeted Therapeutics and Regenerative Medicine
-
May 24, 2026, 07:39Shamala Thilarajah: Our Team Receives the NMRC Transition Award for NEUROACT-Stroke
-
May 24, 2026, 05:48Yazan Abou-Ismail: Contributing to the Future of von Willebrand Disease Management